Interpace Diagnostics Group News Today

Interviews with the CEOs of Six Biotech Companies, with Six Strategies to achieve success with their stocks

EyePoint is an ophthalmology company focused on back-of-the-eye diseases -- retinal eye diseases. We have two Phase II studies ongoing right now in very high unmet need, large areas.

Only about half of patients with markedly elevated blood pressure are prescribed appropriate multiple-drug regimens in accordance with the hypertension guidelines, a regional cohort study found.

Allogene Therapeutics (ALLO) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Allogene Therapeutics, with a price target of $43.00. The company’s shares closed last Wednesday at $35.12. According to TipRanks.com, Burns is a 4-star analyst with an average return of 15.5% and a 44.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics. The wor...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) today and set a price target of $11.00. The company’s shares closed last Monday at $4.06. According to TipRanks.com, Chen is a top 100 analyst with an average return of 61.9% and a 50.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. The word on The Street in gener...